Baxter Shares Outstanding 2006-2018 | BAX

Baxter shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Baxter shares outstanding for the quarter ending September 30, 2018 were 0.546B, a 1.97% decline year-over-year.
  • Baxter 2017 shares outstanding were 0.555B, a 0.73% increase from 2016.
  • Baxter 2016 shares outstanding were 0.551B, a 0.36% increase from 2015.
  • Baxter 2015 shares outstanding were 0.549B, a 0.37% increase from 2014.
Baxter Annual Shares Outstanding
(Millions of Shares)
2017 555
2016 551
2015 549
2014 547
2013 549
2012 556
2011 573
2010 594
2009 614
2008 637
2007 654
2006 656
2005 629
Baxter Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 546
Q2 2018 547
Q1 2018 551
Q4 2017 555
Q3 2017 557
Q2 2017 555
Q1 2017 551
Q4 2016 551
Q3 2016 551
Q2 2016 553
Q1 2016 552
Q4 2015 550
Q3 2015 549
Q2 2015 549
Q1 2015 548
Q4 2014 547
Q3 2014 547
Q2 2014 548
Q1 2014 548
Q4 2013 548
Q3 2013 549
Q2 2013 549
Q1 2013 551
Q4 2012 556
Q3 2012 552
Q2 2012 553
Q1 2012 563
Q4 2011 573
Q3 2011 571
Q2 2011 575
Q1 2011 581
Q4 2010 594
Q3 2010 587
Q2 2010 596
Q1 2010 602
Q4 2009 614
Q3 2009 612
Q2 2009 612
Q1 2009 621
Q4 2008 637
Q3 2008 638
Q2 2008 638
Q1 2008 644
Q4 2007 654
Q3 2007 651
Q2 2007 661
Q1 2007 659
Q4 2006 656
Q3 2006 661
Q2 2006 659
Q1 2006 648
Q4 2005 629
Q3 2005 632
Q2 2005 626
Q1 2005 623
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $35.393B $10.561B
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter India is a wholly owned subsidiary of Baxter International Inc. Baxter India believes in engaging collaboratively with patients, healthcare providers, governments and non - government organizations to help change the lives of millions of people by providing safe, effective and affordable products and therapies.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.543B 19.40
Abbott Laboratories (ABT) United States $126.526B 25.64
Stryker (SYK) United States $64.420B 24.28
Boston Scientific (BSX) United States $51.491B 26.02
Zimmer Biomet Holdings (ZBH) United States $23.875B 15.48
Smith & Nephew SNATS (SNN) United Kingdom $16.038B 0.00
ResMed (RMD) United States $14.846B 28.31
Perrigo (PRGO) Ireland $8.596B 13.05
Bio-Rad Laboratories (BIO) United States $8.274B 52.91
Canopy Growth (CGC) Canada $8.174B 0.00
Hill-Rom Holdings (HRC) United States $6.270B 19.88
Aurora Cannabis (ACB) Canada $6.172B 33.68
Haemonetics (HAE) United States $5.727B 50.36
ICU Medical (ICUI) United States $4.968B 27.68
Insulet (PODD) United States $4.838B 0.00
Agios Pharmaceuticals (AGIO) United States $4.052B 0.00
Hutchison China MediTech (HCM) China $4.010B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.990B 0.00
Neogen (NEOG) United States $3.294B 49.88
NuVasive (NUVA) United States $3.166B 29.46
National Vision Holdings (EYE) United States $3.024B 58.49
Quidel (QDEL) United States $2.507B 32.68
Aphria (APHA) $2.433B 0.00
NxStage Medical (NXTM) United States $1.933B 0.00
Phibro Animal Health (PAHC) United States $1.409B 19.95
AtriCure (ATRC) United States $1.241B 0.00
Cardiovascular Systems (CSII) United States $1.058B 1524.50
VAREX IMAGING (VREX) United States $0.999B 20.07
Meridian Bioscience (VIVO) United States $0.823B 26.23
Surmodics (SRDX) United States $0.794B 121.41
OraSure Technologies (OSUR) United States $0.772B 43.48
Eagle Pharmaceuticals (EGRX) United States $0.755B 24.24
MacroGenics (MGNX) United States $0.740B 0.00
Cerus (CERS) United States $0.716B 0.00
PetIQ (PETQ) United States $0.705B 20.03
Lantheus Holdings (LNTH) United States $0.625B 19.35
Omeros (OMER) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.540B 26.52
Owens & Minor (OMI) United States $0.535B 6.05
Insys Therapeutics (INSY) United States $0.527B 0.00
NanoString Technologies (NSTG) United States $0.521B 0.00
TG Therapeutics (TGTX) United States $0.444B 0.00
Evolus (EOLS) United States $0.403B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.332B 21.45
Cytosorbents (CTSO) United States $0.313B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.264B 0.00
Surface Oncology (SURF) United States $0.225B 0.00
Rockwell Medical (RMTI) United States $0.214B 0.00
BioLife Solutions (BLFS) United States $0.204B 275.00
Bovie Medical (BVX) United States $0.198B 0.00
Chimerix (CMRX) United States $0.172B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.146B 0.00
Fonar (FONR) United States $0.141B 7.06
Imprimis Pharmaceuticals (IMMY) United States $0.123B 0.00
Chembio Diagnostics (CEMI) United States $0.106B 0.00
United-Guardian (UG) United States $0.080B 16.85
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.066B 21.07
InfuSystems Holdings (INFU) United States $0.064B 0.00
CAS Medical Systems (CASM) United States $0.053B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.043B 0.00
Capricor Therapeutics (CAPR) United States $0.028B 0.00
Myomo (MYO) United States $0.024B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.018B 0.00
Senestech (SNES) United States $0.017B 0.00
Akers Biosciences Inc (AKER) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00